Mast cell stabilizers for treatment of hypercytokinemia and viral infection
Inventors
Hyde-Deruyscher, Robin Parish • Hyde-DeRuyscher, Nancy Harlan • Hyde-DeRuyscher, Elicia Kristine
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
The present invention relates to methods for treating hypercytokinemia and viral infections associated with hypercytokinemia using a mast cell stabilizing compound, optionally in combination with an antiviral agent. The invention further relates to compositions and dosage forms comprising mast cell stabilizing agents, optionally with an antiviral agent.
Core Innovation
The partial content describes the use of mast cell stabilizers, including norketotifen, to treat or prevent hypercytokinemia and associated disorders such as systemic inflammatory response syndrome. The independent claims recite administering a therapeutically effective amount of norketotifen or a pharmaceutically acceptable salt thereof to treat or ameliorate hypercytokinemia caused by systemic inflammatory response syndrome, or systemic inflammatory response syndrome associated with hypercytokinemia.
The supplied summary characterizes the approach as suppressing excessive innate inflammatory mediator release while preserving adaptive pathogen clearance. It also describes use in combination with additional therapeutic agents or physical treatments. The background section is not included in the partial content, so the specific problem identified in that section is not explicitly described in patent.
Claims Coverage
The supplied claims identify two independent claims: claim 1 covers treatment of hypercytokinemia caused by systemic inflammatory response syndrome, and claim 3 covers treatment of systemic inflammatory response syndrome associated with hypercytokinemia. The claim coverage includes four inventive features and related dependent claim refinements.
Treatment of hypercytokinemia caused by systemic inflammatory response syndrome
Claim 1 recites administering norketotifen or a pharmaceutically acceptable salt thereof to treat or ameliorate hypercytokinemia caused by systemic inflammatory response syndrome.
Treatment of systemic inflammatory response syndrome associated with hypercytokinemia
Claim 3 recites administering norketotifen or a pharmaceutically acceptable salt thereof to treat or ameliorate systemic inflammatory response syndrome associated with hypercytokinemia.
Additional therapeutic agent or physical treatment
Dependent claims add an additional therapeutic agent for systemic inflammatory response syndrome or a physical treatment. The specified physical treatments are surgery, transplantation, plasmapheresis, modulation of temperature, or a combination thereof.
Administration with an additional therapeutic agent
Dependent claims specify administration of norketotifen or its pharmaceutically acceptable salt and an additional therapeutic agent in the same composition or in separate compositions.
The claims cover two treatment methods using norketotifen or its pharmaceutically acceptable salt: one directed to hypercytokinemia caused by SIRS and the other to SIRS associated with hypercytokinemia. Dependent claims add an additional therapeutic agent, a physical treatment, and composition options for administering the agents.
Stated Advantages
The claimed methods treat or ameliorate hypercytokinemia caused by systemic inflammatory response syndrome, or systemic inflammatory response syndrome associated with hypercytokinemia.
Documented Applications
Use of norketotifen or a pharmaceutically acceptable salt to treat or prevent hypercytokinemia and associated disorders such as systemic inflammatory response syndrome, or systemic inflammatory response syndrome associated with hypercytokinemia.
Interested in licensing this patent?